Welcome to the THALOMID REMS™ program
THALOMID® (thalidomide) in combination with dexamethasone is indicated for the treatment of patients with
newly diagnosed multiple myeloma (MM).
THALOMID is indicated for the acute treatment of the cutaneous manifestations of moderate to severe
erythema nodosum leprosum (ENL).
THALOMID is not indicated as monotherapy for such ENL treatment in the presence of moderate to severe neuritis.
THALOMID is also indicated as maintenance therapy for prevention and suppression of the cutaneous
manifestations of ENL recurrence.
Important information about THALOMID and the THALOMID Risk Evaluation
and Mitigation Strategy (REMS)™ program
THALOMID is contraindicated in pregnant females and females capable of becoming pregnant. Females of reproductive potential may be treated with THALOMID provided adequate precautions are taken to avoid pregnancy
To avoid embryo-fetal exposure, THALOMID is only available under a restricted distribution program called "THALOMID REMS™" (formerly known as the S.T.E.P.S.® program)
Only prescribers and pharmacies certified by the THALOMID REMS™ program can prescribe and dispense THALOMID to patients who are enrolled and meet all the conditions of the THALOMID REMS™ program
The goals of the THALOMID risk evaluation and mitigation strategy are as follows:
To prevent the risk of embryo-fetal exposure to THALOMID
To inform prescribers, patients, and pharmacists on the serious risks and safe-use conditions for THALOMID
THALOMID® is a registered trademark of Celgene Corporation.
THALOMID REMS™ is a trademark of Celgene Corporation.
© 2015 year of origin. Celgene Corporation, www.celgene.com.
This website is intended for residents of the United States only.